Data security and has become a hot issue in pharmaceuticals over the past few years because FDA and other regulatory agencies have issued many warning letters and import alerts due to lack of data integrity in records. Recently FDA has published a guideline in the form of question and answer for the compliance of data integrity in firms. These documents clarify the expectations of the FDA from pharmaceutical firms regarding data integrity.
According to the concept of ALCOA data should be Attributable, Legible, Contemporaneous, Original and Accurate. Data should be accurate and unchanged during its whole life. Data must be recorded at the time of the activity is being done and it should not be backdated.
The use of computers in industries is common and in the age of computers, it is easy to generate fake records. Sometimes it happens unknowingly but in most of the cases, employee generates the fake data to take a short cut or due to excess workload. Following are some strategies to minimize the risk of data integrity issues in pharmaceutical industries.
As you know data integrity has its importance in the industries. The impact of unprotected records can be dangerous for its reliability as well as product quality. I have written many articles on data integrity because the data quality is not a focal point for many companies and issues are being raised by regulatory agencies. Record maintenance is entirely deferent from data integrity. It is not necessary that a properly maintained record would have integrity and accuracy.
The use of computers in industries is common and in the age of computers, it is easy to generate fake records. Sometimes it happens unknowingly but in most of the cases, employee generates the fake data to take a short cut or due to excess workload. Following are some strategies to minimize the risk of data integrity issues in pharmaceutical industries.
No comments:
Post a Comment
Please don't spam. Comments having links would not be published.